Aboleris Pharma
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.
3
Funding Rounds
$61.0m
Money raised
Overview
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.
-
Website:
- Business model: B2B
- Headquarters: Nantes
- Social accounts:
Funding
Funding series
Funding Series Analysis
The company Aboleris Pharma has raised a total of $61m in funding over 3 rounds.
Key Insights:
- AbolerIS Pharma September 2023 Series A Funding Round: $29m
- AbolerIS Pharma September 2023 Series A Funding Round: $29m
- AbolerIS Pharma November 2020 Seed Funding Round: $3m
AbolerIS Pharma September 2023 Series A Funding Round
$29m
AbolerIS Pharma September 2023 Series A Funding Round
$29m
AbolerIS Pharma November 2020 Seed Funding Round
$3m
Industries
Aboleris Pharma is active in the following industries: